These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
116 related items for PubMed ID: 20392995
1. Thioredoxin and thioredoxin reductase expression in thyroid cancer depends on tumour aggressiveness. Lincoln DT, Al-Yatama F, Mohammed FM, Al-Banaw AG, Al-Bader M, Burge M, Sinowatz F, Singal PK. Anticancer Res; 2010 Mar; 30(3):767-75. PubMed ID: 20392995 [Abstract] [Full Text] [Related]
2. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM. Anticancer Res; 2003 Mar; 23(3B):2425-33. PubMed ID: 12894524 [Abstract] [Full Text] [Related]
3. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Soini Y, Kahlos K, Näpänkangas U, Kaarteenaho-Wiik R, Säily M, Koistinen P, Pääakkö P, Holmgren A, Kinnula VL. Clin Cancer Res; 2001 Jun; 7(6):1750-7. PubMed ID: 11410516 [Abstract] [Full Text] [Related]
4. Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation. Lincoln DT, Singal PK, Al-Banaw A. Anticancer Res; 2007 Jun; 27(6B):4201-18. PubMed ID: 18225592 [Abstract] [Full Text] [Related]
5. Thioredoxin is associated with proliferation, p53 expression and negative estrogen and progesterone receptor status in breast carcinoma. Turunen N, Karihtala P, Mantyniemi A, Sormunen R, Holmgren A, Kinnula VL, Soini Y. APMIS; 2004 Feb; 112(2):123-32. PubMed ID: 15056229 [Abstract] [Full Text] [Related]
7. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Kakolyris S, Giatromanolaki A, Koukourakis M, Powis G, Souglakos J, Sivridis E, Georgoulias V, Gatter KC, Harris AL. Clin Cancer Res; 2001 Oct; 7(10):3087-91. PubMed ID: 11595699 [Abstract] [Full Text] [Related]
9. Expression of thioredoxin in patients with Graves' disease. Kihara M, Kontani K, Yamauchi A, Miyauchi A, Nakamura H, Yodoi J, Yokomise H. Int J Mol Med; 2005 May; 15(5):795-9. PubMed ID: 15806300 [Abstract] [Full Text] [Related]
10. Nuclear factor kappaB transactivation is increased but is not involved in the proliferative effects of thioredoxin overexpression in MCF-7 breast cancer cells. Freemerman AJ, Gallegos A, Powis G. Cancer Res; 1999 Aug 15; 59(16):4090-4. PubMed ID: 10463612 [Abstract] [Full Text] [Related]
13. Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses cisplatin-induced apoptosis in pancreatic cancer. Arnold NB, Ketterer K, Kleeff J, Friess H, Büchler MW, Korc M. Cancer Res; 2004 May 15; 64(10):3599-606. PubMed ID: 15150118 [Abstract] [Full Text] [Related]
14. Effects of buried charged groups on cysteine thiol ionization and reactivity in Escherichia coli thioredoxin: structural and functional characterization of mutants of Asp 26 and Lys 57. Dyson HJ, Jeng MF, Tennant LL, Slaby I, Lindell M, Cui DS, Kuprin S, Holmgren A. Biochemistry; 1997 Mar 04; 36(9):2622-36. PubMed ID: 9054569 [Abstract] [Full Text] [Related]
15. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Tonissen KF, Di Trapani G. Mol Nutr Food Res; 2009 Jan 04; 53(1):87-103. PubMed ID: 18979503 [Abstract] [Full Text] [Related]